CMT-3 targets different α-synuclein aggregates mitigating their toxic and inflammogenic effects

Parkinson's disease (PD) is a neurodegenerative disorder for which only symptomatic treatments are available. Repurposing drugs that target α-synuclein aggregation, considered one of the main drivers of PD progression, could accelerate the development of disease-modifying therapies. In this wor...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Sci Rep
Autors principals: González-Lizárraga, Florencia, Ploper, Diego, Ávila, César L., Socías, Sergio B., dos-Santos-Pereira, Mauricio, Machín, Belén, Del-Bel, Elaine, Michel, Patrick Pierre, Pietrasanta, Lía I., Raisman-Vozari, Rita, Chehín, Rosana
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7679368/
https://ncbi.nlm.nih.gov/pubmed/33219264
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-020-76927-0
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars